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Kaposi’s sarcoma (KS) is a highly vascular tumour and is the most common neoplasm associated with human immunodeficiency virus
(HIV-1) infection. Growth factors, in particular vascular endothelial growth factor (VEGF), have been shown to play an important role
in its development. The role of insulin-like growth factors (IGFs) in the pathophysiology of different tumours led us to evaluate the
role of IGF system in KS. The IGF-I receptors (IGF-IR) were identified by immunohistochemistry in biopsies taken from patients with
different AIDS/HIV-related KS stages and on KSIMM cells (an established KS-derived cell line). Insulin-like growth factor-I is a growth
factor for KSIMM cells with a maximum increase of
3H-thymidine incorporation of 130727.6% (Po0.05) similar to that induced by
VEGF and with which it is additive (281713%) (Po0.05). Moreover, specific blockade of the receptor (either by a IR3 antibody or
by picropodophyllin, a recently described selective IGF-IR tyrosine phosphorylation inhibitor) induced KSIMM apoptosis, suggesting
that IGF-IR agonists (IGF-I and -II) mediate antiapoptotic signals for these cells. We were able to identify an autocrine loop essential
for KSIMM cell survival in which IGF-II is the IGF-IR agonist secreted by the cells. In conclusion, IGF-I pathway inhibition is a promising
therapeutical approach for KS tumours.
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The development of Kaposi’s sarcoma (KS) is characterised by
spindle cell (SC) proliferation, inflammatory cell infiltration,
neoangiogenesis, oedema and invasiveness. It is the most frequent
tumour in AIDS patients and, although antiretroviral therapy
seems to improve the prognosis of patients with AIDS-KS tumours,
almost all patients eventually develop disseminated disease (Bower
et al, 1999). The lack of specific therapy is a driving force towards
the identification of possible new therapeutic targets.
Kaposi’s sarcoma origin and pathogenesis is still debated. Along
with infectious agents such as HIV-1 and HHV-8 (also known as
KS-associated herpes virus) (the subject of a recent review
(Boshoff and Weiss, 2002)), cytokines and growth factors appear
to play an important role in KS development (Ensoli and Sturzl,
1998; Skobe et al, 1999). Vascular endothelial growth factor
(VEGF) is suggested to have a central paracrine/autocrine role for
tumour growth (Masood et al, 1997). However, blocking VEGF
with a specific antibody seems to affect mainly the vascularisation
of the tumour rather than the tumour cell behaviour itself
(Samaniego et al, 2002). Therefore, a specific alternative approach,
which would interfere with tumour proliferation and survival,
could be of value for KS therapy. KS cells display not only a
dysregulation of the proliferation, but they are also resistant to
apopotosis (Mori et al, 1996; Buttiglieri et al, 2004a). Insulin-like
growth factor-I (IGF-I) is an important mitogen and antiapoptotic
factor in various tissues. It can act as a systemic hormone or as a
local growth factor. The systemic levels of IGF-I are positively
influenced mainly by growth hormone (GH) and by nutrition
(Yakar et al, 2002). The biological effects of IGF-I are mediated
through the activation of IGF-I receptors (IGF-IR) which exhibit
the same affinity for IGF-II and can also be activated by high doses
of insulin (LeRoith and Roberts Jr, 2003). Experimental and
epidemiological evidence highlights the involvement of IGF-I
system in different malignancies (Khandwala et al, 2000), as well as
an essential role in angiogenesis along with VEGF (Smith et al,
1999). Interference with IGF-IR function in several neoplastic
diseases seems to be an attractive pharmaceutical approach
especially nowadays when specific and easy-to-deliver compounds
are available (LeRoith and Helman, 2004). To our knowledge, no
previous studies have addressed the role of IGF-I on KS biology.
In this study, we have used a KS cell line (KSIMM) to evaluate
the importance of IGF-I on KS biology. These cells produce highly
angiogenic and haemorrhagic tumours when injected in nude
mice, mimicking the human disease (Albini et al, 1997). We make
the novel observation that IGF-I receptors (IGF-IR) are essential
for both proliferation and antiapoptotic signals. Moreover, we
identified an autocrine loop essential for KSIMM cell survival, in
which IGF-II is the tumoral ligand for IGF-IR. The presence of
IGF-IR on the surface of AIDS-KS tumour cells in situ suggests that
our experimental observation can be used as a basis for the
pharmacological IGF-IR interference for the treatment of patients
Received 11 August 2004; revised 10 December 2004; accepted 4
January 2005; published online 5 April 2005
*Correspondence: Dr S-B Catrina;
E-mail: Sergiu-Bogdan.Catrina@molmed.ki.se
British Journal of Cancer (2005) 92, 1467–1474
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
swith this disease. In this respect, a novel specific IGF-IR tyrosine
phosphorylation blocker, picropodophyllin (PPP), which has
shown antitumoral properties in vivo (Girnita et al, 2004), induced
apoptosis in KSIMM cells.
MATERIALS AND METHODS
Materials
Recombinant human IGF-I was provided by Pharmacia (Stockholm,
Sweden), IGF-II was a kind gift from Eli Lily (Indianapolis),
VEGF-165 was purchased from R&D Systems (Abingdon, UK) and
human insulin from Novo Nordisk (Denmark). Cell culture
reagents were from Gibco (Stockholm, Sweden),
3H-thymidine
was purchased from NEN Life Sciences Products and scintillation
liquid (Ultima Gold) from Perkin-Elmer (Boston, USA). Mouse
monoclonal antibody against the a subunit of IGF-IR (2C8), used
for immunohistochemistry, and mouse monoclonal-anti-CD34
(endothelial antigen) were from Santa Cruz Biotechnology, Inc.
(USA); anti-mouse IgG and peroxidase-linked whole antibody were
from Amersham (Uppsala, Sweden), and mouse monoclonal
anti-IGF-IR antibody (aIR 3), used for cell culture, was obtained
from Oncogene Research Products (Boston, USA). Picropodophyl-
lin was prepared as described previously (Girnita et al, 2004). All
other reagents used for immunohistochemistry were from DAKO
(Denmark).
Immunohistochemistry for detecting IGF-IR and CD34
expression
Diagnostic, surgical biopsies of AIDS-related KS lesions from
patients in Tanzania (Dept. Pathology, Muhimbili Medical School,
Dar El. Salaam) (n¼8, four nodular and four patch lesions) were
formalin-fixed, embedded in paraffin and sectioned for histo-
pathological and immunohistochemical evaluation. The patients’
HIV status was evaluated by serology using the Wellcozyme
Recombinant anti-HIV-1 ELISA VK56 (Murex Diagnostics, Tor-
onto, Canada). Serial tissue sections were evaluated for IGF-IR and
CD34 expression using ABC immunohistochemistry with an anti-
avidin enhancement technique (van Gijlswijk et al, 1996). Paraffin
sections were deparaffinised, rehydrated and pretreated by
microwave heating in citrate buffer, pH 6, and endogenous
peroxidase activity blocked by hydrogen peroxide (3% for
30min), as described previously (Kaaya et al, 2000). After rinsing
and blocking with normal horse serum, serial sections were
incubated with anti-IGF-IR or anti-CD34 antibody for 2h at 371C.
This was followed by rinsing and incubation with biotinylated
secondary antibody (horse anti-mouse) for 40min and another
rinsing and incubation with ABC peroxidase (30min). To increase
the sensitivity of ABC, a biotinylated antibody against avidin
(30min) and a second ABC peroxidase treatment (30min) was
performed. Bound ABC was visualised by incubation with fresh
3,30-diamino benzidine (DAB) for 2–10min. Negative controls
using isotype-matched antibody were included and placenta
biopsies were used as IGF-IR positive control.
Insulin-like growth factor-I receptor immunostaining in KSIMM
cells cultured on chamber slides and fixed in paraformaldehyde
(PFA) 4% in PBS, pH 7.4, was performed using the monoclonal
mouse IgG1 antibody at a concentration of 10mgml
 1 as described
previously (Catrina et al, 2002). Negative controls using isotype-
matched IgG were included.
Cell culture
KSIMM cells, kindly provided by Dr A Albini (Istituto Nazionale
per la Ricerca sul Cancro, Genova, Italy), were cultured in DMEM
supplemented with 2mML -glutamine, 100IUml
 1 penicillin and
streptomycin and 10% heat-inactivated bovine serum (FBS) in a
humidified atmosphere with 5% CO2 at 371C. Proliferation
experiments and MTT assay experiments were carried out in 96-
well microtest plates (plated at a density of 1 10
4cellswell
 1)
with five replicates for each concentration, for FACS analysis in
100mm Petri dishes and for TdT-mediated dUTP nick end
labelling (TUNEL) assay in chamber slides (Nalge Nunc, Naper-
ville, USA) with duplicates. The experiments were repeated at least
three times. At 24h following plating, the cells were rinsed once
with medium without FBS, serum-starved for 24h, rinsed again
with medium without FBS and incubated with testing substances
for the times indicated, as volumes less than 0.01%.
Evaluation of cell proliferation by
3H-thymidine
incorporation assay
After 44h of incubation with testing substances, 1mCi
3H-
thymidine was added to each well. After 4h, the cells were washed
twice with 0.9% ice-cold NaCl. The cell-associated radioactivity,
precipitated with 5% TCA, was determined by liquid scintillation
counting. Results are expressed as a percentage of the control,
untreated cells.
MTT assay
After 44h of incubation with PPP or control (DMSO), the number
of viable cells was evaluated using the MTT viability assay, as we
described previously (Catrina et al, 1999). Briefly, 20ml MTT (3-[4,
5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide; thyazo-
lil blue) (5mgml
 1) in DMEM was added to each well. After 4h of
incubation, the formazan crystals, produced by viable cells, were
dissolved with 100ml 0.004 N HCl-isopropyl alcohol for 5min. The
cell survival rate was calculated from the optical density at 570nm
after subtracting the optical density at 620nm. Results are
expressed as a percentage of the control treated cells.
Evaluation of cell apoptosis
TdT-mediated dUTP nick end labelling assay and morphological
evaluation TdT-mediated dUTP nick end labelling was carried
out using a fluorescein-labelled in situ cell death detection
kit (Roche, Bromma, Sweden) as described previously (Catrina
et al, 2002). Briefly, the cells fixed in PFA were permeabilised
with 0.1% Triton X-100 in 0.1% sodium citrate solution for 2min
on ice and 50ml TUNEL reaction reagent/sample was applied
over the cells. After 60min incubation at 371C in the dark, the
slides were examined by fluorescence microscopy. For
light microscopy evaluation, the slides were incubated for
30min, 371C with 50ml converter POD in PBS 0.1% BSA, and
exposed to DAB solution (0.5mgml
 1) (Sigma). Finally, the
samples were counterstained with Meyer haematoxylin. The
classical morphological apoptosis criteria of nuclear condensation,
membrane blebbing and formation of apoptotic bodies combined
with TUNEL-positive reaction of the nuclei were used to evaluate,
by light microscopy, the apoptotis, which was expressed as an
apoptotic index (percentage of apoptotic cells from 500 counted
cells).
FACS with annexin V/propidium iodide
Following incubation with specified substances, cells were
trypsinised and then stained with annexin V and propidium
iodide as specified by the manufacturer (R&D Systems, Oxon, UK)
and analysed by flow cytometry. In order to compare the effect of
different substances on the survival rate, we generated histograms
for annexin V fluorescence, and positive cells were gated and
expressed as percentages from the total number of acquired cells.
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sInsulin-like growth factor-I and IGF-II assay in KSIMM cell
culture medium
Insulin-like growth factor-I and IGF-II in conditioned KSIMM
cultured medium were assayed after HPLC separation from IGFBPs
by radioimmunoassay (RIA) using high-affinity antibodies. The
IGF-I assay was previously described (Bang et al, 1991) and has a
detection limit 0.07ngml
 1 with intra- and interassay coefficients of
variation 4 and 11%. Respectively, IGF-II assay was performed
under the same conditions as IGF-I assay, except that IGF-II labelled
by the chloramine T method was used as a tracer and an anti-IGF-II
mouse monoclonal antibody (S1F2) was used as first antibody in a
final concentration of 1:150000 (Upstate Biotechnology, Lake
Placid, NY, USA), and the separation was performed using an
anti-mouse IgG (Sac-Cel, IDS Ltd, Boldon, UK). The detection limit
was 0.05ngml
 1, with an intra-assay coefficient of variation of 3%.
The HPLC separation of the IGFs from IGFBPs was performed
using a size-exclusion chromatography after incubation for 30min
at 221Co f5 0 ml conditioned culture medium with 50ml column
buffer (5 ) (acetic acid 0.2 M, trimethylamine 0.1 M and Triton X-
100 0.5gl
 1, pH 2.8 adjusted with sulphuric acid) as described
previously (Crawford et al, 1992).
Statistical analysis
All values are presented as mean7s.e. The data were analysed by
one-way ANOVA with a Tukey post hoc test; or Kruskall–Wallis
one-way analysis of variance with Dunn’s method, as appropriate,
using SigmaStat v2.03 SPSS Inc.
RESULTS
Insulin-like growth factor-I receptors are expressed in
AIDS-related KS tumours
The expression of IGF-IR was evaluated in eight cases of AIDS-
related KS tumour biopsies by immunohistochemistry. A large
proportion of the KS tumour SCs, identified by morphology and
positive immunostaining for CD34 in serial sections, showed
positive staining with the anti-IGF-IR antibody. In addition, most
vessels and slit-lining cells, and some infiltrating leucocytes, were
positively stained (Figure 1A, B). No significant difference was
seen between patch (early) and nodular (late) lesions in the
immunostaining pattern (data not shown).
Insulin-like growth factor-I stimulates KSIMM cell
proliferation
The effect of IGF-I on the proliferation of KSIMM cells was
investigated using the
3H-thymidine incorporation. Insulin-like
growth factor-I stimulated the proliferation of KSIMM cells in vitro
in a dose-dependent manner by a maximum increase of 130727.6%
(Po0.05 for concentrations higher than 1ngml
 1) (Figure 2A). The
effect of IGF-I on the proliferation of KSIMM cells was of the same
magnitude as VEGF, postulated to be an essential growth factor for
KS cells (maximum increase of 151.9730.5%; Po0.05 for concen-
trations higher than 1ngml
 1) (Figure 1B). The combination of
10ngml
 1 of IGF-I (maximally effective stimulatory concentration)
and VEGF (0.1–100ngml
 1) had an additive effect, increasing the
proliferation rate by a maximum of 281713% (Po0.05) (Figure 1B).
The growth-promoting effects of IGF-I on KSIMM cells are
mediated by IGF-IR
To investigate what receptor mediates the effect of IGF-I, we have
compared the growth-promoting effect of des (1–3) IGF-I (agonist
for IGF-IR, which binds minimally to the IGFBPs) with insulin.
Des (1–3) IGF-I stimulates the growth rate of KSIMM cells in a
Figure 1 AIDS-KS biopsies show immunoreactivity for IGF-IR. Serial
sections of paraffin-embedded KS biopsies were evaluated for IGF-IR and
CD34 expression. (A) Immunohistochemistry for IGF-IR showing reactivity
in tumour SCs (small arrow) and some infiltrating leukocytes (long arrow).
Original magnification  250. The inset panel shows IGF-IR reactivity in
spindle tumour cells at a higher magnification ( 500). (B) Immunohis-
tochemistry for CD34 showing reactivity in tumour SCs. (C) Negative
control with mouse IgG1.The bar represents 15mm.
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sdose–response manner with an EC50 around 0.58ngml
 1 far more
potent than insulin that, at 100ngml
 1, reaches less then 50% of
the maximal effect of IGF-I. This suggests that IGF-IR is the
mediator of IGF-I effects on KSIMM cells (Figure 3A). The
presence of this receptor in KSIMM cells was further demonstrated
by immunohistochemistry. As presented in Figure 3B, KSIMM
cells are specifically immunopositive for the a subunit of IGF-IR
with both cytoplasmic and pericellular patterns. The functional
involvement of these receptors as mediators of the IGF-I growth-
promoting effect was demonstrated by the complete abolishment
of the IGF-I effect when the cells were co-incubated with a IR3
monoclonal blocking antibody (Flier et al, 1986) (Figure 3C).
Insulin-like growth factor-I receptor mediates
antiapoptotic signals in KSIMM cells
The profound inhibition of
3H-thymidine incorporation in KSIMM
cells after specific blockade of the IGF-IR prompted us to
investigate a potential antiapoptotic effect mediated through
IGF-IR. Treatment of the cells with IGF-I had no significant effect
on the apopotic rate of KSIMM cells (apoptotic index 1.370.3 vs
3.870.7% in control), but blocking IGF-IR with a IR3 monoclonal
antibody induced apoptosis. This effect was documented both by
the positivity of KSIMM cells for Annexin V (Figure 4A) and by
typical apoptotic morphology and TUNEL-positive staining
(Figure 4B) after treatment with a IR3 (apoptotic index 21.870.7
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Figure 2 Insulin-like growth factor-I increases in a dose-dependent
manner proliferation of KSIMM cells with potency similar to VEGF, with
which it has an additive effect. (A) KSIMM cells, starved for 24h, were
exposed to either IGF-I or vehicle for 48h when proliferation was assessed
by
3H-thymidine incorporation. The values represent means7s.e.m. from
five different experiments (*Po0.05). (B) KSIMM-starved cells were
exposed to either VEGF alone (0.1–100ngml
 1) or to the combination of
VEGF and 10ngml
 1 IGF-I. Cell proliferation was assessed by
3H-thymidine
incorporation after 48h incubation. The values represent means7s.e.m.
from three different experiments (*Po0.05 as control,
#Po0.05 as
equivalent VEGF concentration).
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Figure 3 Insulin-like growth factor-I growth-promoting effect on KSIMM
cells is mediated by IGF-IR. (A) KSIMM cells, starved for 24h, were
exposed to either des(1–3) IGF-I or insulin for 48h when proliferation was
assessed by
3H-thymidine incorporation. The values represent mean-
s7s.e.m. from three different experiments. (B) Immunohistochemical
identification of IGF-IR in KSIMM. The left panel shows intra and pericellular
positivity of the KSIMM cells for IGF-IR. The right panel shows the negative
control with mouse IgG1. (C) KSIMM cells, starved for 24h, were exposed
to IGF-I alone (10 and 100ngml
 1) or in combination with the specific
blocking antibody for IGF-IR, a IR3. After 48h, proliferation was assessed by
3H-thymidine incorporation. The values represent means7s.e.m. from
three experiments (*Po0.05).
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propidium iodide cells were observed following treatment,
confirming the specific proapoptotic effect of IGF-IR blocking.
Insulin-like growth factor-II is the endogenous agonist of
an autocrine loop in KSIMM cells
Specific blocking of IGF-IR resulted in decreased spontaneous
3H-thymidine incorporation, as well as induction of apoptosis,
suggesting the presence of an autocrine loop essential for both
proliferation and survival of these tumoral cells. Thus, we
measured the putative ligands for IGF-IR (IGF-I and IGF-II) in
KSIMM conditioned media after separation from IGFBPs. Insulin-
like growth factor-II has been detected in 72h conditioned media
at a concentration of 4.1ngml
 1, while IGF-I was under the
detection limit of our assay. As expected, exogenous IGF-II had the
same growth-promoting effect as IGF-I on KSIMM cells, with a
maximum
3H-thymidine incorporation of 157721% (Po0.05).
Picropodophyllin, a specific inhibitor of IGF-IR activity,
induces apoptosis in KSIMM cells
The presence of IGF-IR in the tumour specimens from patients
with AIDS-KS coupled with the essential functional role of the
IGF-IR in KSIMM biology determined us to investigate the effect
of PPP, a new, specific IGF-IR tyrosine kinase inhibitor, which has
been shown to have antitumoral proprieties in vivo (Girnita et al,
2004). Treatment of KSIMM cells with PPP induced a dose-
dependent cell death with an IC50 at 95nM (Figure 5A), in the range
reported for other IGF-IR-positive tumours (Girnita et al, 2004).
Treatment of KSIMM cells with 100nM PPP induced apoptosis as
documented by Annexin V positivity (Figure 5B) and by typical
apoptotic morphological cell appearance and positive immuno-
staining for TUNEL (Figure 5C) (22.171.5 vs 1.370.5% in control-
treated cells) (Po0.001).
DISCUSSION
KS is the leading cause of cancer death in areas with endemic AIDS
(Parkin et al, 1999). Even though highly active antiretroviral
therapy (HAART) has led to a decrease of the KS tumour burden,
AIDS patients are still at high risk of developing KS when they
discontinue HAART or when the therapy is not available.
Developing a therapy specific to the tumour cell biology is
imperative for these patients.
Interference with growth factors of importance in KS biology is a
logical approach which has already been successful in different
malignancies (for a review, see Shawver et al, 2002). Here, we show
the presence of the IGF-IR in biopsies taken from patients with
AIDS/HIV-related KS, and further demonstrate that the IGF system
is essential for cell growth and for mediating antiapoptotic signals
in a KS cell line (KSIMM) that has the characteristics of the KS SCs
and produce large highly vascularised tumours when injected s.c.
in nude mice (Albini et al, 1997). Moreover, we suggest that PPP, a
small molecule that specifically interferes with IGF-IR function, is
a potential effective therapy.
Insulin-like growth factor-I receptor was found in all the KS
tumours studied. No clear difference in IGF-IR cell expression
between early and late KS stages was observed, suggesting a
constant IGF-IR expression during characteristic multistage
development of KS tumours.
The relevance of the functional role of these receptors in KS
biology was further demonstrated in KSIMM cells where
exogenous IGF-I induced a dose-dependent stimulation of cell
proliferation. Insulin-like growth factor-I has been shown to be a
growth factor for different tumours and prospective epidemiolo-
gical data suggested that high circulating levels of IGF-I confer
increased risk for different solid tumours (reviewed by LeRoith
and Roberts Jr, 2003). For KSIMM cells, IGF-I had the same
growth-promoting potency as VEGF, which is postulated to be one
of the most important growth factors for KS tumours (Arasteh and
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Figure 4 Insulin-like growth factor-I receptor mediates antiapoptotic signals for KSIMM cells. (A) KSIMM cells were treated, after starving for 24h, with
either IGF-I (100ngml
 1), a IR3 (1mgml
 1) or vehicle for 24h and analysed by FACS for annexin V binding. (B) KSIMM cells were starved for 24h and then
treated with either IGF-I (100ngml
 1), a IR3 (1mgml
 1) or vehicle for 48h, fixed in PFA 4% and then stained for TUNEL and counterstained with Meyer
haematoxylin (magnification  500).
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sHannah, 2000). Furthermore, IGF-I and VEGF have an additive
effect on the KSIMM proliferation rate, which suggests that these
two growth factors may act at least in part independently to
promote growth. Vascular endothelial growth factor and IGF-I
cellular pathways have been reported to either act independently
(Hellstrom et al, 2001) or to interact (Smith et al, 1999) in normal
endothelial cells. The relationship between VEGF and IGF-I
signalling pathways including those involved in cell survival in
KS is the focus of ongoing studies.
Both IGF-IR ligands (IGF-I and IGF-II) have high affinity for
IGFBPs, molecules that can compete with their binding to the
receptor. Thus, to investigate the potential receptor involved in
IGF effect on KSIMM cells, we have used des(1–3)-IGF-I, a full
agonist for IGF-IR that binds minimally to IGFBPs (Clemmons
et al, 1992).
The effect of IGF-I on KSIMM cells is mediated through IGF-IR.
This is suggested by the higher potency of des(1–3)-IGF-I
as compared to insulin, as well as the complete abolition of the
IGF-I effect through IGF-IR-blocking antibody (a IR3). Moreover,
we demonstrated that both KSIMM cells as well as KS tumours
express IGF-1R. Even though hybrid receptors with insulin cannot
be excluded (Pandini et al, 2002), the effect of PPP (specific
blocker of the beta subunit of IGF-IR (Girnita et al, 2004)) on
KSIMM apoptosis suggests that the IGF-IR is the main mediator
of IGF system on these cells. The decrease of
3H-thymidine
incorporation in KSIMM cells after treatment with the IGF-IR-
blocking antibody a IR3 powerfully suggested the presence of an
autocrine loop in these cells. We have in consequence analysed
the secretion of both IGF-I and IGF-II by KSIMM cells because
both are equally potent ligands for these receptors. Both IGF-I
and IGF-II mRNA expression have been documented previously in
AIDS-KS cultured cells (Weich et al, 1991) but, to our knowledge,
there is no previous report on their secretion in KS cells. To
avoid the known interferences of IGFBPs with IGF-I and IGF-II
assays, which could give false-positive results, we have first
separated them by HPLC. We were able to detect IGF-II but not
IGF-I in the conditioned medium. The presence of the IGF-II as
member of the endogenous IGF system is not surprising. There is
clear evidence of its upregulation in different tumours (Zhang
et al, 1997).
We were able to show that the autocrine loop plays an essential
role for protecting the KSIMM from apoptosis. This was
demonstrated by blocking the IGF-IR in two ways: by using a
IR3 (a specific blocking antibody) or by using PPP (specific
blocker of the beta subunit of IGF-IR (Girnita et al, 2004)).
Exposure of the KSIMM cells to either of these compounds
induced apoptosis as demonstrated by both externalisation of
phosphatidylserine, TUNEL staining and typical apoptotic mor-
phological changes. We did not observe any significant difference
in the apoptosis rate after treatment with IGF-I, which is in line
with the reported low spontaneous apoptosis rate of these cells
(Buttiglieri et al, 2004b).
In addition to autocrine sources, it may be that KS tumours are
stimulated by endocrine IGFs from the circulation. Albini et al
(1999) made the observation that the in vivo administration of
somatostatin decreases the development of KS-like lesions in mice
inoculated with KSIMM cells, despite an absence of somatostatin
receptors on the tumoral cell surface. In the light of our data on the
effect of IGF-I in these cells, we speculate that somatostatin, by
inhibiting pituitary GH release, may also have had an antitumoral
effect via a decrease in endocrine IGF-I, as it was demonstrated for
other tumors (Wu et al, 2003).
Numerous attempts have been made to block the IGF system for
treatment of tumours (reviewed by Surmacz, 2003) but most of the
methods had different problems as lack of specificity, difficulty of
drug delivery, etc. One of the most promising approach is to use
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Figure 5 Picropodophyllin, a specific inhibitor of IGF-IR activity, induces apoptosis in KSIMM cells. (A) KSIMM cells were treated with different
concentrations of PPP for 48h and subjected to MTT assay for the last 4h. (B) KSIMM cells were treated, after starving for 24h, with PPP (1mgml
 1)o r
vehicle for 24h and analysed by FACS for annexin V binding. (C) KSIMM cells were starved for 24h and then treated with PPP (1mgml
 1) or vehicle for
48h, fixed in PFA 4% and then stained for TUNEL and counterstained with Meyer haematoxylin (magnification  500).
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(LeRoith and Helman, 2004). In this light, we have also tested
the effect of PPP, which has been shown to be a potent and specific
inhibitor of the IGF-IR tyrosine kinase (Girnita et al, 2004).
Treatment of the KSIMM cells with PPP induced a dose-dependent
apoptosis in the same dose range reported for other IGF-IR-
positive cells. We would like to point out that the compound is
active even in the presence of FCS, which shows that blocking the
IGF system overrides the survival signals from other factors.
Specifically inhibiting the IGF-IR tyrosine kinase has been proved
to be a successful approach for other small molecules as well
(Garcia-Echeverria et al, 2004; Mitsiades et al, 2004; Warshamana-
Greene et al, 2004).
In conclusion, we have demonstrated that IGF system is
essential for proliferation and survival in a KS cell line, which
has characteristics similar to the human disease and we suggest
that targeting the IGF-IR could represent a powerful candidate for
KS therapy.
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